Built by Grok 4.6 High

MO | Earnings Review — Q2 2026

Verdict: HOLD — quality cash compounder, cooling growth optics. Q2 was a narrow adj EPS miss (−$0.02 / −1.3%) with a narrow revenue beat (+0.2% net-of-excise). Management raised only the low end of FY26 adj EPS to $5.61–$5.72 (mid $5.665, still ~1.5¢ under Street $5.68). Adj EPS grew +2.8% YoY — still positive, but decelerating hard from the +7–10% run-rate through mid-2025. Net revenue essentially flat YoY after a one-quarter optical flip in Q1. Post-print path: 7/29 close $74.92 → 7/30 $67.94 (−3.9%) → ~$68.31 by analysis date.

Print (Daloopa + FMP): Adj diluted EPS $1.48 (+2.8% YoY vs $1.44; −1.3% vs FMP $1.50). Net revenues $6,111M (+0.1% YoY vs $6,102M). Street-definition revenue (net of excise) $5.356B vs $5.346B. Smokeable adj OCI $3,018M (+2.4% YoY), margin 64.8% (+30 bps). Oral adj OCI $460M (−8.0%) on on! PLUS trial investment. Gross margin 62.5% (−58 bps YoY) — first mild YoY compression after multi-year expansion. H1 adj EPS $2.80 (+4.9% YoY).

Guidance: Low end raised $5.56 → $5.61; high unchanged $5.72; growth +3.5% to +5.5% off $5.42 FY25 base. CapEx stepped to $375–$450M. No revenue, margin, or quarterly EPS guide (Altria standard). NJOY ACE not in 2026 guide.

Tone: Confident on smokeable profitability and total-portfolio RGM (Basic + Cowboy Cut); conservative on numbers (high end not raised after an EPS miss); explicit 2H investment for on! PLUS 12 mg (Q3) and flavors (Q4); consumer still under pressure (gas/inflation/geopolitics). First full CEO print for Sal Mancuso with Heather Newman as CFO.

Contradictions (3 hard): (C-1) “fourth consecutive quarter” of moderated cig declines claimed on both Q1 and Q2 calls; (C-2) year-start guide assumed limited enforcement volume impact, then Q1–Q2 attributed better volumes primarily to cross-category moderation; (C-3) buyback residual $72M at Q1 vs $665M at Q2 — almost certainly a $720M transcript mis-hear.

Forward catalysts: on! PLUS 12 mg national Q3 + flavors Q4; duty-drawback / FET true-up balanced across Q3–Q4; industry cig declines holding ~−5% inv-adj; PMI ZYN Aurora commercial production + MRTP competitive pressure; $665M buyback residual through YE26; next print ~2026-10-29.

Read-first: Top-line still structurally soft (smokeable decline) but 2026H1 flipped net revenue to modest YoY growth after years of declines; pricing + mix continue to support adj EPS, though Q2'26 adj EPS growth decelerated to +2.8% from +7–10% through mid-2025. Smokeable adj OCI remains the earnings engine; oral is investment-mode near-term.

A. Revenue drivers → consolidated P&L

| Metric | 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | 2024Q4 | 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 | |---|--:|--:|--:|--:|--:|--:|--:|--:|--:|--:|--:|--:| | Smokable net rev ($mm) | 5,572 | 5,274 | 4,906 | 5,495 | 5,540 | 5,263 | 4,622 | 5,357 | 5,387 | 5,119 | 4,758 | 5,392 | | Smokable YoY % | −5.3% | −3.3% | −3.6% | −5.6% | −0.6% | −0.2% | −5.8% | −2.5% | −2.8% | −2.7% | +2.9% | +0.7% | | Oral tobacco net rev ($mm) | 685 | 674 | 651 | 711 | 722 | 692 | 654 | 753 | 689 | 706 | 669 | 713 | | Oral YoY % | +2.2% | +6.6% | +3.7% | +4.6% | +5.4% | +2.7% | +0.5% | +5.9% | −4.6% | +2.0% | +2.3% | −5.3% | | Consolidated net rev ($mm) | 6,281 | 5,975 | 5,576 | 6,209 | 6,259 | 5,974 | 5,259 | 6,102 | 6,072 | 5,846 | 5,428 | 6,111 | | Net rev YoY % | −4.1% | −2.2% | −2.5% | −4.6% | −0.4% | −0.0% | −5.7% | −1.7% | −3.0% | −2.1% | +3.2% | +0.1% | | Gross profit ($mm) | 3,699 | 3,499 | 3,280 | 3,675 | 3,808 | 3,604 | 3,249 | 3,850 | 3,812 | 3,631 | 3,506 | 3,820 | | Gross margin % | 58.9% | 58.6% | 58.8% | 59.2% | 60.8% | 60.3% | 61.8% | 63.1% | 62.8% | 62.1% | 64.6% | 62.5% | | GM YoY (bps) | +245 | +112 | +61 | +146 | +195 | +177 | +296 | +391 | +194 | +178 | +281 | −58 | | Adj. diluted EPS ($) | 1.28 | 1.18 | 1.15 | 1.31 | 1.38 | 1.29 | 1.23 | 1.44 | 1.45 | 1.30 | 1.32 | 1.48 | | Adj EPS YoY % | 0.0% | 0.0% | −2.5% | 0.0% | +7.8% | +9.3% | +7.0% | +9.9% | +5.1% | +0.8% | +7.3% | +2.8% | | GAAP diluted EPS ($) | 1.22 | 1.16 | 1.21 | 2.21 | 1.34 | 1.79 | 0.63 | 1.41 | 1.41 | 0.66 | 1.30 | 1.37 |

Smokeable net-of-excise (pricing power lens): Q2'26 4,660 vs Q2'25 4,570 (+2.0% YoY) even as reported smokeable net rev only +0.7% — price/mix still outrunning volume.

Absolute net revenue — 12 quarters ($M)

B. Segment profit drivers (smokeable / oral adj OCI)

| Metric | 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | 2024Q4 | 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 | |---|--:|--:|--:|--:|--:|--:|--:|--:|--:|--:|--:|--:| | Smokeable adj OCI ($mm) | 2,741 | 2,568 | 2,451 | 2,827 | 2,935 | 2,709 | 2,518 | 2,947 | 2,956 | 2,643 | 2,676 | 3,018 | | Smoke adj OCI YoY % | — | — | — | — | +7.1% | +5.5% | +2.7% | +4.2% | +0.7% | −2.4% | +6.3% | +2.4% | | Smoke adj OCI margin % | 59.6% | 59.0% | 60.2% | 61.6% | 63.1% | 61.2% | 64.4% | 64.5% | 64.4% | 60.4% | 65.1% | 64.8% | | Smoke margin YoY (bps) | — | — | — | — | +350 | +220 | +420 | +290 | +130 | −80 | +70 | +30 | | Oral adj OCI ($mm) | 455 | 408 | 435 | 451 | 464 | 461 | 435 | 500 | 460 | 440 | 436 | 460 | | Oral adj OCI YoY % | — | — | — | — | +2.0% | +13.0% | 0.0% | +10.9% | −0.9% | −4.6% | +0.2% | −8.0% | | Oral adj OCI margin % | 69.3% | 63.1% | 69.5% | 65.6% | 66.8% | 69.5% | 69.2% | 68.7% | 69.2% | 64.5% | 67.4% | 66.7% | | on! can shipments (mm) | — | — | 33.3 | 41.2 | 41.9 | 43.9 | 39.3 | 52.1 | 42.2 | 44.2 | 46.2 | 49.9 |

Adj EPS — 12 quarters ($)

Annual trend (FY2021–FY2025)

| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |---|--:|--:|--:|--:|--:| | Smokable net rev ($mm) | 22,866 | 22,476 | 21,756 | 21,204 | 20,485 | | Smokable YoY % | −1.0% | −1.7% | −3.2% | −2.5% | −3.4% | | Oral tobacco net rev ($mm) | 2,608 | 2,580 | 2,667 | 2,776 | 2,802 | | Oral YoY % | +3.0% | −1.1% | +3.4% | +4.1% | +0.9% | | Consolidated net rev ($mm) | 26,013 | 25,096 | 24,483 | 24,018 | 23,279 | | Net rev YoY % | −0.5% | −3.5% | −2.4% | −1.9% | −3.1% | | Gross margin % | 53.8% | 56.8% | 58.3% | 59.8% | 62.5% | | GM YoY (bps) | +399 | +298 | +158 | +148 | +265 | | Smokeable adj OCI ($mm) | 10,424 | 10,726 | 10,710 | 10,922 | 11,064 | | Smoke adj OCI YoY % | +3.1% | +2.9% | −0.1% | +2.0% | +1.3% | | Smoke adj OCI margin % | 57.6% | 59.0% | 59.9% | 61.6% | 63.4% | | Adj. diluted EPS ($) | 4.61 | 4.84 | 4.95 | 5.12 | 5.42 | | Adj EPS YoY % | +5.7% | +5.0% | +2.3% | +3.4% | +5.9% | | GAAP diluted EPS ($) | 1.34 | 3.19 | 4.57 | 6.54 | 4.12 |

Three trends jump off the table:

1. Revenue growth is not accelerating — chronic annual declines through FY25; H1'26 is a modest +1.6% flip that already faded in Q2 to +0.1%. Treat Q1'26 green print as base-effect (lapping Q1'25 −5.7% trough).
2. Gross margin multi-year expansion is pausing — FY21 53.8% → FY25 62.5% (+~870 bps cumulative); Q2'26 first mild YoY dip (−58 bps). Expansion rate peaked mid-2025 (+391 bps).
3. Adj EPS still compounds mid-single digit, powered by smokeable pricing/OCI + capital return + ABI — not organic top-line. Peak YoY +9.9% (Q2'25) → +2.8% (Q2'26).

| Dimension | Direction | Evidence | |---|---|---| | Net revenue | Inflecting decline → flat / slight + | 2026Q1 +3.2%, 2026Q2 +0.1%; H1'26 +1.6% | | Smokeable revenue | Stabilizing (less negative → slightly +) | Q1 +2.9% / Q2 +0.7% as volume declines moderated | | Oral revenue | Decelerating / volatile | Q2'26 −5.3%; on! cans 49.9mm −4.2% vs 52.1mm | | Gross margin | Multi-year up; Q2 first mild YoY dip | FY25 62.5%; Q2 62.5% vs 63.1% (−58 bps) | | Smokeable adj OCI | Slowing $ growth; margins still elevating | Q2 OCI +2.4%; margin +30 bps (vs +290 bps in Q2'25) | | Adj EPS | Growing, growth decelerating | Peak +9.9% → +2.8%; H1 +4.9% |

Q2 2026 was a slight EPS miss with a slight revenue beat — economically near in-line. Adj EPS −$0.02 / −1.3%; revenue (net of excise) +$10M / +0.2%. L12Q EPS beat rate 58%; L4Q 50% (B–M–B–M alternating). Miss magnitudes have not deteriorated (−$0.01 to −$0.03 band over three years).

Heatmap (last 8 quarters)

Full history (L12Q adj EPS)

| Quarter | Report date | Cons. EPS (FMP) | Actual (Daloopa) | Variance $ | Variance % | B/M | |---|---|---:|---:|---:|---:|:--:| | ▶ 2026Q2 | 2026-07-30 | $1.50 | $1.48 | −$0.02 | −1.3% | M | | 2026Q1 | 2026-04-30 | $1.24 | $1.32 | +$0.08 | +6.5% | B | | 2025Q4 | 2026-01-29 | $1.32 | $1.30 | −$0.02 | −1.5% | M | | 2025Q3 | 2025-10-30 | $1.44 | $1.45 | +$0.01 | +0.7% | B | | 2025Q2 | 2025-07-30 | $1.39 | $1.44 | +$0.05 | +3.6% | B | | 2025Q1 | 2025-04-29 | $1.19 | $1.23 | +$0.04 | +3.4% | B | | 2024Q4 | 2025-01-30 | $1.28 | $1.29 | +$0.01 | +0.8% | B | | 2024Q3 | 2024-10-31 | $1.35 | $1.38 | +$0.03 | +2.2% | B | | 2024Q2 | 2024-07-31 | $1.34 | $1.31 | −$0.03 | −2.2% | M | | 2024Q1 | 2024-04-25 | $1.15 | $1.15 | $0.00 | 0.0% | I | | 2023Q4 | 2024-02-01 | $1.17 | $1.18 | +$0.01 | +0.9% | B | | 2023Q3 | 2023-10-26 | $1.29 | $1.28 | −$0.01 | −0.8% | M |

| Window | EPS beat rate | Pattern | |---|---|---| | L12Q | 7/12 = 58.3% (7B / 4M / 1I) | Mixed | | L4Q | 2/4 = 50% | Alternating B–M–B–M | | Miss magnitude | −$0.01 to −$0.03 | Stable, not deteriorating |

Management variance explanation (not framed as “miss vs street”): (1) growth timing played out differently than year-start plan; (2) smoke-free / portfolio investments (on! PLUS trial, Cowboy Cut RGM) pressuring near-term EPS; (3) duty-drawback FET credit lag — export vols up but credit flat seq on application timing; (4) consumer under pressure → discount mix dilutes price realization (smokeable realization 4.5%; Marlboro retail ~+7% offset by Basic mix); (5) ABI equity earnings $158M (+21.5% YoY) were a positive, not a miss driver. Despite the EPS miss, management raised the FY low end — treating H1 as on-track, not broken.

Headline: Altria raised only the low end of FY26 adj diluted EPS to $5.61–$5.72 (from $5.56–$5.72), lifting midpoint by +$0.025 to $5.665 — still ~1.5¢ below Street FY26 consensus of $5.68. High end unchanged at +5.5% growth. Range narrowed from $0.16 to $0.11. No revenue, margin, or quarterly EPS guidance.

Guidance evolution (FY26 adj EPS)

| Call | Date | Guide Low | Guide High | Mid | Growth vs $5.42 | Action | |---|---|---:|---:|---:|---|---| | FY25 / Q4 | 2026-01-29 | $5.56 | $5.72 | $5.640 | +2.5%–+5.5% | Initial (2H-weighted) | | 2026Q1 | 2026-04-30 | $5.56 | $5.72 | $5.640 | +2.5%–+5.5% | Reaffirm; phasing → more balanced | | 2026Q2 | 2026-07-30 | $5.61 | $5.72 | $5.665 | +3.5%–+5.5% | Raise low / narrow |

Waterfall — prior mid → new mid → consensus

Guide vs expectations

| Metric | Prior Mid | New Low | New High | New Mid | Consensus | vs Prior | vs Cons | |---|---:|---:|---:|---:|---:|---:|---:| | Adj diluted EPS ($) | 5.640 | 5.610 | 5.720 | 5.665 | 5.68 | +$0.025 | −$0.015 | | Adj EPS growth YoY | +4.0% mid | +3.5% | +5.5% | +4.5% | +4.8% | +50 bps | −30 bps | | CapEx ($M) | 337.5 mid | 375 | 450 | 412.5 | N/A | +$75 mid | N/A |

Implied 2H bridge (H1 adj EPS = $1.32 + $1.48 = $2.80):

| Scenario | FY26 EPS | Implied 2H | 2H YoY vs ~$2.75 H2'25 | Comment | |---|---:|---:|---:|---| | New low | 5.61 | $2.81 | ~+2.2% | Embeds reinvestment + consumer caution | | New mid | 5.665 | $2.87 | ~+4.2% | Aligns if duty drawback lands | | New high | 5.72 | $2.92 | ~+6.2% | Clean 2H + limited extra opex | | Street FY26 | 5.68 | $2.88 | ~+4.7% | Slightly above mgmt mid |

Analyst question correctly noted low end is still below H1 growth rate — guidance embeds deceleration and/or reinvestment in 2H.

Other guided / directional items

| Category | Guided? | New (post-Q2) | Notes | |---|---|---|---| | CapEx FY26 | Yes | $375–$450M (L / H) | Was $300–$375M; USSTC consolidation + smoke-free mfg | | on! PLUS 12 mg | Directional | National in Q3 | Resumed FL/NC/TX in Q2 | | on! PLUS flavors | Directional | Q4 (Blueberry Mint, Mango Pineapple) | Investment spend in guide | | Duty drawback / FET | Directional | Higher export + more balanced Q3/Q4 credit | Q2 flat seq on timing | | NJOY ACE | Explicit exclusion | Not returning in 2026 | Re-enter “at some point” with discipline | | Revenue / margins / quarterly EPS | No | — | Altria standard |

Tone scorecard (Q4 → Q1 → Q2)

| Dimension | Q4'25 init | Q1 reaffirm | Q2 narrow | |---|---|---|---| | EPS confidence | Cautious open band | “Prudent to reaffirm” | “Really pleased we could narrow” | | Consumer language | Economic pressure | Gas up; refunds temporary | Persistent inflation/gas/geo | | Investment stance | Smoke-free + mfg build | “Not under-investing” | Explicit step-up for on! PLUS SKUs | | Guidance posture | Wide open range | Hold despite strong Q1 | Low-end raise only |

Tone verdict: Not defensive on the franchise; not promotional on the guide. Conservative signaling after a Q2 EPS miss — refusing to lift the high end with 2H investment ahead.

Key assumptions embedded

| Assumption | Q2 update | Risk if wrong | |---|---|---| | EPS phasing | Timing “played out differently”; 2H still has duty-drawback + investment | 2H comps + investment put low end at risk | | Cigarette volumes | 4th consecutive moderated quarter (~−5% inv-adj); elasticity still ~−0.35 | Macro / illicit re-accel reverses moderation | | Duty drawback | Timing friction acknowledged; 2H still expected | Timing slip or export match shortfall | | Smoke-free opex | 12 mg national Q3 + flavors Q4 | Could cap high-end EPS if trial costs exceed plan | | Consumer macro | Still under pressure; explicit monitor language | Trade-down intensifies → price realization / mix hit |

Window: Q3'24 → Q2'26. All growth YoY. Accel = change in the YoY rate vs prior quarter's YoY rate (bps).

| Metric | Q3'24 | Q4'24 | Q1'25 | Q2'25 | Q3'25 | Q4'25 | Q1'26 | Q2'26 | |---|---:|---:|---:|---:|---:|---:|---:|---:| | Revenue YoY % | −0.4% | −0.0% | −5.7% | −1.7% | −3.0% | −2.1% | +3.2% | +0.1% | | Rev Accel (bps) | n/a | +33 | −567 | +396 | −126 | +85 | +536 | −307 | | EPS YoY % | +7.8% | +9.3% | +7.0% | +9.9% | +5.1% | +0.8% | +7.3% | +2.8% | | EPS Accel (bps) | n/a | +151 | −237 | +297 | −485 | −430 | +654 | −454 |

Revenue YoY % — 8-quarter line

Adj EPS YoY % — 8-quarter line

Inflection map

| Period | Signal | Magnitude | Read | |---|---|---:|---| | Q1'25 | Rev trough | YoY −5.7%; accel −567 bps | Hardest revenue print in the window | | Q2'25 | EPS peak | YoY +9.9% (8-qtr high) | Pricing + buybacks overpowered volume | | Q3'25–Q4'25 | EPS deceleration cascade | −485 then −430 bps → YoY only +0.8% | Growth compresses; Q4 is EPS trough | | Q1'26 | Dual positive inflection | Rev +3.2% (+536 bps); EPS +7.3% (+654 bps) | First green rev after 6 negative quarters — easy base is large part of math | | Q2'26 (just-reported) | Deceleration on both | Rev +0.1% (−307 bps); EPS +2.8% (−454 bps) | Inflection fades once easy Q1 base rolls off |

Plain-English: Revenue is stable-to-flat, not accelerating; Q1'26 green was an easy-comp artifact that already faded. EPS is positive but decelerating into the just-reported quarter; still tracks company FY26 guide mid if H2 holds. Quality of earnings growth remains price/OCI/margin + capital return, not organic top-line expansion.

Bottom line: MO is a flat-revenue, mid-single-digit adj EPS compounder whose Q1'26 top-line “inflection” was mostly base effect and already reversed in Q2'26.

Catalyst stack for H2'26–2027 is product and regulatory, not pure EPS beat/miss. High-conviction near-term: (1) on! PLUS 12 mg national Q3, (2) on! PLUS flavor SKUs Q4, (3) whether FDA enforcement sustains moderated cig industry declines. Competitive risk rose the week of the print: PMI’s Aurora ZYN plant entered commercial production (July 2026) and FDA granted ZYN MRTP on 20 SKUs (June 30, 2026).

Supporting KPI trajectory

| Metric | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 | YoY (Q2) | |---|---:|---:|---:|---:|---:|---:| | Adj diluted EPS ($) | $1.44 | $1.45 | $1.30 | $1.32 | $1.48 | +2.8% | | Smokeable adj OCI ($M) | $2,947 | $2,956 | $2,643 | $2,676 | $3,018 | +2.4% | | Domestic cig vol (M sticks) | 16,066 | 16,192 | 15,290 | 13,867 | 15,554 | −3.2% | | MO cig vol, inv-adj | −10.5% | −9.0% | −7.0% | −4.0% | −4.5% | Moderating | | Industry cig vol, inv-adj | −8.5% | −8.0% | −6.5% | −5.0% | −5.0% | 4th moderated print | | on! shipment cans (M) | 52.1 | 42.2 | 44.2 | 46.2 | 49.9 | −4.2% | | on! retail share (oral) | 8.7% | 8.7% | 7.7% | 7.8% | 8.6% | +0.3 pp YoY; +0.8 pp seq | | Oral adj OCI ($M) | $500 | $460 | $440 | $436 | $460 | −8.0% | | Buybacks ($M, quarter) | $274 | $112 | $288 | $280 | $55 | H1 $335M; $665M left |

Prioritized catalyst table

| # | Catalyst | Timing | Mgmt signal | Commentary | |---|---|---|---|---| | 1 | on! PLUS 12 mg national | Q3 2026 | National expansion planned Q3; higher strength “important”; ~120k stores | Highest-visibility H2 volume catalyst. Success = sequential share + inv-adj can growth without further oral OCI collapse | | 2 | on! PLUS flavor extensions | Q4 2026 | Blueberry Mint, Mango Pineapple across 6/9/12 mg | Key differentiator vs capacity-rich ZYN | | 3 | FDA enforcement + illicit crackdown | Ongoing; guidance ~May 2026 | “Constructive”; seizures >$250M Q2; dual need authorization + sustained enforcement | Core thesis stabilizer for smokeable OCI | | 4 | NJOY ACE marketplace return | Not 2026 | Supplemental PMTA in; re-enter “at some point” with discipline | Asymmetric optionality, not H2'26 EPS | | 5 | Duty drawback / FET refunds | 2H 2026 | Higher export + balanced Q3–Q4 credit | Mechanical 2H EPS bridge; watch Q3 true-up | | 6 | FY26 adj EPS vs guide / street $5.68 | Through YE26; next print ~10/29 | Raised low; H1 $2.80 (+4.9%) | Q3 proof of 2H math is near-term price catalyst | | 7 | PMI ZYN capacity + MRTP | Commercial prod July 2026; MRTP Jun 30 | Helix acknowledges intensifying competition | Largest competitive catalyst (bearish for on! share) | | 8 | USSTC consolidation + CapEx | CapEx $375–$450M; multi-year | ~$88M Q2 specials mostly consolidation | Near-term noise; medium-term cost structure | | 9 | Share repurchase ($665M remaining) | Expires YE26 | Dividend first; Q2 buybacks only $55M | Catalyst if executed into soft tape | | 10 | Marlboro Cowboy Cut + Basic | Expanding 2026 | Protect premium profit pool (~85% of cig profitability) | Defensive for share; mixed for price realization | | 11 | Litigation specials | Ongoing | Q2 tobacco & health items $67M pre-tax | Headline/bonding risk; not base-case earnings path | | 12 | Menthol ban | Withdrawn Jan 2025 | Off table | Cleared multi-year overhang (residual political risk) | | 13 | Leadership transition | CEO post Jun 4 AGM; first full print = Q2 | Continuity message; narrowed guide | Soft landing for transition | | 14 | Q3 2026 earnings | ~2026-10-29 | Early 12 mg read + FET balance | Next hard data catalyst |

Watchlist (next 1–2 quarters)

| Priority | Watch item | Bull signal | Bear signal | |---|---|---|---| | 1 | on! cans + oral retail share | Inv-adj can growth; share ≥9% oral | Share stalls; promo-driven OCI margin <65% | | 2 | Industry cig inv-adj decline | Holds ≤5–6% | Widens back toward 8%+ | | 3 | FET / duty drawback true-up | Clear step-up Q3→Q4 | Another “timing” miss | | 4 | ZYN competitive (capacity + MRTP) | on! holds/gains pouch share | on! pouch share keeps losing | | 5 | FY26 guide vs street at Q3 | Reaffirm or raise; path to ≥$5.68 | Low-end only / defensive language | | 6 | Litigation specials | Normalize to historical run-rate | Elevated quarter or adverse cert |

Bull path: Moderated combustible declines + successful on! PLUS 12 mg/flavor cycle under clearer FDA enforcement, funding dividend and finishing the buyback, with NJOY as free 2027+ option.
Bear path: ZYN capacity/MRTP share theft + consumer trade-down diluting price realization + launch opex without share → guide defend mode.

Scorecard: 10 Well Answered · 4 Deflected/Avoided (14 exchanges across 7 analyst seats). Management open and specific on reported drivers; deflections clustered on forward unit outlook, product-level quantification (Cowboy Cut), and e-vapor re-entry timing.

| # | Analyst | Topic | Badge | |---:|---|---|---| | 1 | Matt Smith (Stifel) | 2H guidance vs H1; investments vs duty drawback | Well answered | | 2 | Matt Smith (Stifel) | Cowboy Cut share trajectory & sourcing | Deflected — positioning only, zero quantification | | 3 | Bonnie Herzog (GS) | Duty-drawback lag; smokeable OCI drivers | Well answered | | 4 | Bonnie Herzog (GS) | Moderating cig declines; Basic comps; elasticity | Well answered (no 2H volume forecast) | | 5 | Pallav Mittal (Barclays) | Gas correlation; shipment vs inv-adj gap unwind | Deflected on inventory unwind | | 6 | Pallav Mittal (Barclays) | on! PLUS feedback, 12 mg, retention, shipment lag | Well answered | | 7 | Eric Serotta (MS) | Premium/discount mix into 2H | Well answered | | 8 | Eric Serotta (MS) | on! PLUS consumer sourcing | Well answered | | 9 | Faham Baig (UBS) | Price/mix step-down vs Basic share | Well answered | | 10 | Faham Baig (UBS) | FDA policy; PMTA pipeline; NJOY | Well answered (posture; light on full pipeline) | | 11 | Damian McNeela (DB) | Support for classic on! alongside PLUS | Well answered | | 12 | Damian McNeela (DB) | E-vapor category return timing | Deflected — timing not announced | | 13 | Theresa for Priya Ohri-Gupta (Barclays) | 2026/2027 debt refinancing | Well answered | | 14 | (partial) | 2H cig volume path / Basic lap | Soft edge — “we don’t talk about future volume trends” |

Highest-signal deflections

| Topic | Street wanted | Management gave | Why it matters | |---|---|---|---| | Cowboy Cut share & sourcing | Share trajectory; cannibalization | Heritage + RGM framing only | Need mix/price realization math | | Shipment vs inv-adj gap unwind | Will ~120–130 bps shipment outperformance reverse in 2H? | Elasticity (−0.35) + portfolio story | Inventory can reverse and fake volume resilience | | E-vapor / NJOY re-entry timing | When / how Altria re-enters regulated vapor | Intent + supplemental PMTA; no date | Optionality value stays unanchored | | 2H cigarette volume path | Will company cig vols worsen H2 as Basic comps toughen? | Driver framework; no unit path | Floor raise without unit path leaves 2H risk |

Highest-signal well-answered themes

1. Management confidence is in profit, not units — narrowed FY26 adj EPS while refusing forward cigarette volume guidance; classic Altria: price + mix + capital return carry the print.
2. Discount is a controlled bleed — Basic gains and Cowboy Cut framed as RGM retention tools so smokers stay inside PM USA / Marlboro family, not a permanent mix flip management wants to accelerate.
3. on! PLUS is the offensive story — share +0.8 pp seq to 8.6%, 120k-store footprint, 12 mg national Q3 and flavors Q4; shipment noise (comps/inventory) explained.
4. Duty drawback is a timing item, not a miss — explicit Q3/Q4 balanced FET credit is one of the few forward cash/P&L bridges volunteered.
5. Elasticity still −0.35 — pricing power intact; mix/trade-down is the flex.

Street pressure points into Q3: (a) inv-adj cig declines stay near ~5% as Basic comps toughen; (b) Marlboro price realization as Cowboy Cut and Basic dilute; (c) on! PLUS sequential share after 12 mg national; (d) any hard NJOY re-entry signal.

Three hard contradictions plus two acknowledged tensions, ranked by materiality. Branding: red-border alert cards.

| # | Topic | Severity | Likely cause | |---|---|---|---| | C-1 | “Fourth consecutive” ordinal repeated Q1 and Q2 | High (discipline) | Script/boilerplate error | | C-2 | Limited enforcement impact (guide) vs primary driver (results) | Medium (most investable) | Year-start assumption wrong | | C-3 | Buyback residual $72M vs $665M chain | Medium | Likely “$720M” ASR mis-hear | | T-1 | H2-weighted → more balanced phasing | Tension | Explicit revision | | T-2 | Enforcement impact vs illicit still large (same Q4 call) | Tension | Growth vs absolute framing |

Areas checked and found consistent: FY26 guide path (one-direction raise); Marlboro share of premium (59.4% → 59.5% → 59.6%); on! national rollout trajectory; oral investment drag narrative; Basic/discount strategy; duty-drawback lag explanation; NJOY “not in 2026”; debt/EBITDA ~1.9–2.0x; CEO transition.

Headline: Management paints a pressured U.S. low-end consumer (elevated gas, inflation exceeding wage growth, geopolitics) driving trade-down into discount cigarettes, while cig industry volume declines continue to moderate because illicit disposable e-vapor enforcement + category saturation reduce cross-category leakage — net constructive for U.S. combustibles peers and legal smoke-free players if FDA enforcement holds.

Macro frame (nicotine-consumer, not Fed)

Altria does not give a broad macro framework (no Fed funds path, no CPI forecast). Macro color is almost entirely nicotine-consumer disposable income and category-flow.

| Theme | Management statement | Implication | |---|---|---| | Consumer still stressed into 2H26 | Mancuso: “keep an eye on the financial health of the consumer… remains under pressure” | Watch 2H volumes, mix, promo intensity | | Gas + inflation elevated | Geopolitical climate as primary driver of elevated gas/inflation | Read-through to other discretionary / CPG low-end SKUs | | Inflation vs wages | Newman: discount growth from “persistent discretionary income pressures… inflation exceeding overall wage growth” | Structural trade-down; wage lag = ongoing discount share risk for premium CPG | | Elasticity still holds | Price elasticity coefficient “of negative 0.35% continues to hold steady” | Pricing power intact; mix headwind is the flex | | Macro offset by cross-category | Unsettled macro “more than offset by the moderation in cross-category movement” | Enforcement/saturation is the swing factor for industry volumes | | Three-bucket decline model | Secular + price elasticity + (cross-category + macro) | Operational macro for U.S. tobacco modeling |

Key industry facts as read-throughs: Industry inv-adj cig vol ~−5% Q2 and H1 (moderated); MO inv-adj −4.5% Q2 (outperformed); adult vapers ~20M flat YoY; federal seizures >$250M in quarter; discount retail share +2.6 pp YoY — trade-down still live even as total industry volumes improve.

Named entities / competitive set

| Entity | Relationship | Q2 / recent fact | Read-through | |---|---|---|---| | ABI / BUD | Equity stake | Adj equity earnings $158M (+21.5% YoY) | Better near-term for BUD contribution / MO P&L; still pure financial investment | | ZYN / PMI (Swedish Match U.S.) | Pouch competitor | Category ~60% of oral; on! PLUS gaining seq share; ZYN Aurora commercial + MRTP | More competitive for share; category growth still supports pouch thesis | | “Major competitor” supply disruption (2025) | Pouch peer | Tough 2025 comps when competitor had supply issues | Capacity recovery at leader = tougher set for on! | | Deep-discount cig rivals | Competitor | Basic (~35k stores) captures trade-down otherwise lost to competitive discount | Worse for pure-play deep-discount in tracked channels | | Other mass-cigar mfrs | Competitor | Middleton +5% Q2 vs industry −6.4% | Better for MO Black & Mild | | Illicit e-vapor mfrs | Illegal competitors | Seizures, MN AG suit, payment-platform restrictions | Worse for illicit; better for legal cigs/pouches/authorized vapor if sustained | | FDA CTP | Regulator | Enforcement-priorities update “constructive” for clarity; does not replace authorization | Better for authorized / in-review legal players | | ITC / CBP (NJOY ACE) | Legal / trade | Modified products; CBP non-infringement; supplemental PMTA | Better MO optionality; timing still cautious | | KT&G | Collaborator | International modern oral / adjacency | Better for both; limited U.S. combustible threat | | Chinese illicit supply | Gray-market source | Tariffs + enforcement beginning to impact | Worse for China-sourced disposables |

Cross-ticker implications

| If you own / cover… | MO call says… | Better / worse | |---|---|---| | BUD (ABI) | Strong Q2 adj equity earnings (+21.5% YoY) | Better near-term optics | | PM (ZYN) | Category growing; on! PLUS sequential share; prior supply issues lapped | More competitive for share | | BTI / RAI U.S. | Peer legacy-brand pouch strategies; duty-drawback parity; Basic discount war | Competitive pressure in pouches/discount; enforcement helps legal vapor if authorized | | Illicit disposable importers | Seizures, AG litigation, payment blocks | Worse | | U.S. premium CPG / alcohol (low-income skew) | Inflation > wages; gas; geopolitics; trade-down | Soft low-end demand read-through | | Payment / e-comm platforms | Restricting illicit vapor sales | Compliance cost up; legal sellers favored |

Continuity Q4 → Q1 → Q2

| Period | Macro tone | Volume / category tone | |---|---|---| | 2025Q4 | Cumulative inflation; severe pressure; Basic as relief | Industry still deep decline; illicit ~70% of vapor; early enforcement | | 2026Q1 | Challenging; gas spike late Q; tax-refund short-term relief | Industry −5%; 4th consecutive moderation | | 2026Q2 | Same stressed consumer into 2H; no refund offset; elasticity stable | Still −5%; moderation more than offsets macro; enforcement narrative stronger |

Altria printed a near in-line quarter with a narrow adj EPS miss and a low-end-only guide raise that still sits a hair under Street. The franchise remains a high-quality mid-single-digit EPS compounder on a flat revenue base, funded by smokeable pricing power, portfolio RGM (Basic + Cowboy Cut), ABI equity income, and capital return (~6.2% yield at $68.31). Growth momentum is cooling (adj EPS YoY +2.8% vs +7–10% peaks; gross-margin expansion pausing; oral investment drag). Post-print −3.9% day reflects zero tolerance for soft EPS optics even with a floor raise.

HOLD — not a broken story (smokeable OCI still growing, guide intact, balance sheet 1.9x debt/EBITDA, dividend sacred), but not a re-acceleration or re-rating setup until Q3 proves the 12 mg launch and duty-drawback bridge. Three transcript contradictions (ordinal streak, enforcement-assumption flip, buyback residual math) are diligence items; only C-2 is investable (volumes better than year-start plan). Competitive ZYN capacity/MRTP is the main medium-term overhang on oral optionality.

Data sourced from Daloopa